FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890715270> ?p ?o ?g. }

• W2890715270 endingPage "2511" @default.
• W2890715270 startingPage "2502" @default.
• W2890715270 abstract "ConspectusThe common existence of hypoxia in solid tumors has been heavily researched because it renders tumors more resistant to most standard therapeutic methods, such as radiotherapy (RT), chemotherapy, and photodynamic therapy (PDT), and is associated with a more malignant phenotype and poor survival in patients with tumors. The development of hypoxia modulation methods for advanced therapeutic activity is therefore of great interest but remains a considerable challenge. Since the significant development of nanotechnology and nanomedicine, functionalized nanomaterials can be exploited as adjuvant “drugs” for these oxygen-dependent standard therapies or as hypoxia initiators for advanced new therapies to solid tumors.In this Account, we summarize our recent studies on the design and synthesis of nanomaterials with a set of desired chemistry benefits achievable by modulating hypoxia, suggesting a valid therapeutic option for tumors. The investigated strategies can be categorized into three groups: The first strategy is based on countering hypoxia. Considering that O2 deficiency is the major obstacle for the oxygen-dependent therapies, we initially developed methods to supply O2 by taking advantage of the hypoxia-responsive properties of nano-MnO2 or nanomaterials’ photothermal effects for increased intratumoral blood flow. The second approach is to disregard hypoxia. Possible benefits of nanoagents include reducing/eliminating reliance on O2 or making O2 replacements as adjuvants to standard therapies. To this end, we investigated a nano-upconversion/scintillator with the capacity toup-/down-convert near-infrared light (NIR)/X-ray to luminescence in the ultraviolet/visible region fortype-I PDT with minimized oxygen-tension dependency or developed Fe-based nanomaterials for chemodynamic therapy (CDT) without external energy and oxygen participation for efficient free radical killing of deep tumors. The third strategy involves exploiting hypoxia. The unique biological characteristics of hypoxia are exploited to activate nanoagents for new therapies. To address the discrepancy between the nanoagents’ demand and supply within the hypoxia region, a smart “molecule–nano” medicine that stays small-molecule-like in the bloodstream and turns into self-assembled nanovesicles after entry into the hypoxia region was constructed for hypoxia-adaptive photothermal therapy (PTT). In addition to traditional anti-angiogenesis therapy, we prepared Mg2Si nanoparticles by a special self-propagating high-temperature synthesis approach. These nanoparticles can directly remove the intratumoral oxygen via the oxidation reactions of Mg2Si and later efficiently block the rapid reoxygenation via tumor blood vessels by the resultant SiO2 microsheets for cancer starvation therapy. Taken together, these findings indicate that nanomaterials will assume a valuable role for anticancer exploration based on either their properties to make up oxygen deficiency or the use of hypoxia for therapeutic applications." @default.
• W2890715270 created "2018-09-27" @default.
• W2890715270 creator A5006625728 @default.
• W2890715270 creator A5016331689 @default.
• W2890715270 creator A5049232843 @default.
• W2890715270 creator A5060453218 @default.
• W2890715270 creator A5061810022 @default.
• W2890715270 creator A5074140059 @default.
• W2890715270 date "2018-09-20" @default.
• W2890715270 modified "2023-10-15" @default.
• W2890715270 title "Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors" @default.
• W2890715270 cites W1507021713 @default.
• W2890715270 cites W1868554855 @default.
• W2890715270 cites W1963901824 @default.
• W2890715270 cites W1978762833 @default.
• W2890715270 cites W2006202974 @default.
• W2890715270 cites W2024903578 @default.
• W2890715270 cites W2058749153 @default.
• W2890715270 cites W2060385207 @default.
• W2890715270 cites W2064296350 @default.
• W2890715270 cites W2082421539 @default.
• W2890715270 cites W2094304123 @default.
• W2890715270 cites W2102073707 @default.
• W2890715270 cites W2102907645 @default.
• W2890715270 cites W2110155388 @default.
• W2890715270 cites W2114768355 @default.
• W2890715270 cites W2120067572 @default.
• W2890715270 cites W2124496728 @default.
• W2890715270 cites W2131289426 @default.
• W2890715270 cites W2147736101 @default.
• W2890715270 cites W2157259121 @default.
• W2890715270 cites W2168607632 @default.
• W2890715270 cites W2217441961 @default.
• W2890715270 cites W2229268188 @default.
• W2890715270 cites W2256492013 @default.
• W2890715270 cites W2268788143 @default.
• W2890715270 cites W2332024238 @default.
• W2890715270 cites W2401893904 @default.
• W2890715270 cites W2416036924 @default.
• W2890715270 cites W2520458702 @default.
• W2890715270 cites W2569530200 @default.
• W2890715270 cites W2580488838 @default.
• W2890715270 cites W2624235220 @default.
• W2890715270 cites W2729471090 @default.
• W2890715270 cites W2764028271 @default.
• W2890715270 cites W2766554468 @default.
• W2890715270 cites W2768637676 @default.
• W2890715270 cites W2790924898 @default.
• W2890715270 doi "https://doi.org/10.1021/acs.accounts.8b00214" @default.
• W2890715270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30234960" @default.
• W2890715270 hasPublicationYear "2018" @default.
• W2890715270 type Work @default.
• W2890715270 sameAs 2890715270 @default.
• W2890715270 citedByCount "206" @default.
• W2890715270 countsByYear W28907152702019 @default.
• W2890715270 countsByYear W28907152702020 @default.
• W2890715270 countsByYear W28907152702021 @default.
• W2890715270 countsByYear W28907152702022 @default.
• W2890715270 countsByYear W28907152702023 @default.
• W2890715270 crossrefType "journal-article" @default.
• W2890715270 hasAuthorship W2890715270A5006625728 @default.
• W2890715270 hasAuthorship W2890715270A5016331689 @default.
• W2890715270 hasAuthorship W2890715270A5049232843 @default.
• W2890715270 hasAuthorship W2890715270A5060453218 @default.
• W2890715270 hasAuthorship W2890715270A5061810022 @default.
• W2890715270 hasAuthorship W2890715270A5074140059 @default.
• W2890715270 hasConcept C126322002 @default.
• W2890715270 hasConcept C138631740 @default.
• W2890715270 hasConcept C15083742 @default.
• W2890715270 hasConcept C155672457 @default.
• W2890715270 hasConcept C171250308 @default.
• W2890715270 hasConcept C178790620 @default.
• W2890715270 hasConcept C182606246 @default.
• W2890715270 hasConcept C185592680 @default.
• W2890715270 hasConcept C192562407 @default.
• W2890715270 hasConcept C2779081379 @default.
• W2890715270 hasConcept C2781323092 @default.
• W2890715270 hasConcept C2993207723 @default.
• W2890715270 hasConcept C502942594 @default.
• W2890715270 hasConcept C509974204 @default.
• W2890715270 hasConcept C540031477 @default.
• W2890715270 hasConcept C71924100 @default.
• W2890715270 hasConcept C7836513 @default.
• W2890715270 hasConceptScore W2890715270C126322002 @default.
• W2890715270 hasConceptScore W2890715270C138631740 @default.
• W2890715270 hasConceptScore W2890715270C15083742 @default.
• W2890715270 hasConceptScore W2890715270C155672457 @default.
• W2890715270 hasConceptScore W2890715270C171250308 @default.
• W2890715270 hasConceptScore W2890715270C178790620 @default.
• W2890715270 hasConceptScore W2890715270C182606246 @default.
• W2890715270 hasConceptScore W2890715270C185592680 @default.
• W2890715270 hasConceptScore W2890715270C192562407 @default.
• W2890715270 hasConceptScore W2890715270C2779081379 @default.
• W2890715270 hasConceptScore W2890715270C2781323092 @default.
• W2890715270 hasConceptScore W2890715270C2993207723 @default.
• W2890715270 hasConceptScore W2890715270C502942594 @default.
• W2890715270 hasConceptScore W2890715270C509974204 @default.
• W2890715270 hasConceptScore W2890715270C540031477 @default.

• next